Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02215538 · ClinicalTrials.gov registry record · Phase 2
OROS Methylphenidate (Concerta) in the Treatment of Adult ADHD
A Phase 2 study, sponsored by University of Utah.
- Completed
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
NCT02215538 is a Phase 2 study that has completed, run by University of Utah. The registered enrollment target is 47 participants.
The verdict
NCT02215538, a Phase 2 study, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
Study Summary
This study will look at the effectiveness of osmotic release oral system (OROS) methylphenidate (Concerta) in treating attention deficit hyperactvity disorder (ADHD) in adults. Concerta has received FDA approval for childhood ADHD and there is documentation that it is effective in adult ADHD. However this trial will explore its effectiveness in treating symptoms not a part of the Diagnostic and Statistical Manual-III (DSM-III) criteria. Subjects will experience one screening visit and one baseline visit. Those who meet admission criteria will enter the double-blind phase. This will involve two 4-week treatment periods one of which will involve the use of Concerta and the other a placebo pill. Subjects who complete the double-blind phase will be allowed to enter a 180-day, open-label Concerta phase designed to assess long-term effects.
Interventions
- DRUG Placebo
- DRUG OROS methylphenidate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2004-11 |
| Est. Completion | 2006-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02215538
The ClinicalTrials.gov registry entry for NCT02215538 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02215538 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02215538 about?
NCT02215538 is a clinical study titled "OROS Methylphenidate (Concerta) in the Treatment of Adult ADHD". This study will look at the effectiveness of osmotic release oral system (OROS) methylphenidate (Concerta) in treating attention deficit hyperactvity disorder (ADHD) in adults. Concerta has received FDA approval for childhood ADHD and there is documentation that it is effective in adult ADHD. Howeve...
What is the current status of trial NCT02215538?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2004-11. Estimated completion is 2006-06.
What interventions are being tested in trial NCT02215538?
The interventions under investigation include: Placebo (DRUG), OROS methylphenidate (DRUG).
Who is sponsoring clinical trial NCT02215538?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.